Biopharma therapeutic and platform M&A gained clear momentum in Q2 2026, with deal volume rising to 45 transactions from 25 in Q1 and total value, including contingents, climbing to $79.2B from $49.7B; cash value excluding contingents rose to $53.6B from $40.8B. The growth was driven by breadth rather than scale, as average upfront value fell from $2.6B to $1.7B and the median dropped from $1.8B to $780M, indicating a market absorbing a higher volume of comparatively smaller transactions. H1 2026 therefore closed at 70 deals worth $128.9B, including contingents, and $94.4B in cash. By modality, small molecules led with 26 deals worth $45.0B, including contingents, and $38.5B in cash, ahead of biologics at 20 deals and $27.2B, which carried the highest median upfront at $1.0B, while cell therapy added three deals and $8.5B, and gene therapy and vectors stayed marginal at two deals and $396M. By therapy area, cancer dominated with 16 deals and $30.1B in total, including contingents, and $21.2B in cash, followed by dermatology and genitourinary at $11.8B each, the latter resting on the quarter’s largest transaction. In contrast, autoimmune ($6.7B), infectious disease ($4.8B), and a high-count, low-value neurology segment of seven deals and $2.7B completed the leaders.
The headline deals were large-cap and concentrated in cancer, immunology, and platforms. Sun Pharma’s $11.8B acquisition of Organon topped the quarter at a 24% premium, expanding women’s health and biosimilars. AbbVie paid $10.9B for Apogee at a 49% premium for the IL-13 antibody zumilokibart in atopic dermatitis, and GSK paid $10.6B for Nuvalent at a 40% premium for ROS1 and ALK inhibitors in NSCLC. Lilly’s Kelonia deal ($3.3B upfront, up to $3.8B in milestones) and Gilead’s Tubulis deal ($3.2B upfront, up to $1.9B in contingents) added an in vivo CAR-T platform and ADC assets. Marking established pharma paying up for clinical-stage assets and next-generation platforms.
Biopharma therapeutic and platform M&A activity accelerated in Q2 2026, with deal volume rising to 45 transactions from 25 in Q1. Total deal value, including contingent payments, increased to $79.2B from $49.7B, while cash value excluding contingents grew to $53.6B from $40.8B. Despite the stronger activity, the average upfront value declined from $2.6B in Q1 to $1.7B in Q2, and the median decreased from $1.8B to $780M, indicating the quarter’s growth was driven by a higher volume of comparatively smaller transactions. Overall, H1 2026 recorded 70 deals valued at $128.9B, including contingents and $94.4B in cash value.
Biopharma Therapeutic and Platform M&A by Top Modalities – Q2 2026
In Q2 2026, small-molecule-led biopharma therapeutic and platform M&A activity led, with 26 deals valued at $45.0B, including contingent payments and $38.5B in cash value. Biologics, including antibodies, DNA, RNA, and protein technologies, followed with 20 deals worth $27.2B and recorded the highest median upfront value of $1.0B. Cell therapy generated only three deals but accounted for $8.5B in total potential value. Gene therapy and vectors remained the smallest segment, with two deals valued at $396M and an average upfront payment of $148M. Overall, small molecules and biologics dominated the quarter, contributing most deal activity and value, while the combined modality count of 51 indicates that some transactions spanned multiple technology platforms.
Biopharma Therapeutic and Platform M&A by Top Therapy Areas – Q2 2026
Cancer-led biopharma therapeutic and platform M&A activity in Q2 2026, with 16 deals valued at $30.1B, including contingent payments and $21.2B in cash value. Dermatology followed with six deals worth $11.8B, although its median upfront payment of $60M indicates that the total was driven by one or two large transactions. Genitourinary M&A also reached $11.8B through a single exceptionally large acquisition, making it the quarter’s largest individual transaction. Autoimmune and infectious diseases recorded five and four deals worth $6.7B and $4.8B, respectively, supported by relatively strong upfront payments. Ophthalmic, hematologic, and inflammation transactions generated between $2.9B and $3.2B in total value, while Neurology recorded a higher deal count of seven transactions but a lower total value of $2.7B. Cardiovascular ranked last among the leading therapeutic areas, with a single $1.1B transaction. Overall, cancer led both deal activity and value, while the 46 therapeutic area classifications indicate that some transactions covered multiple indications.
Prominent Biopharma Therapeutics and Platforms M&A in Q2 2026
Sun Pharma acquiring Organon – April 2026
Sun Pharmaceutical Industries agreed to acquire Organon for approximately $11.8B in enterprise value, including debt, through a $14.00 per share cash offer representing a 24% one-day premium to the last closing price. Organon has a debt of $8.6B and a cash balance of $574M. The acquisition strengthens Sun’s position in women’s health, branded generics, and biosimilars, while expanding its portfolio across 150 countries. The deal is expected to increase Sun’s revenue to $12.4B, support its ranking among the top 25 global pharma companies, and enhance EBITDA and cash flows to aid deleveraging, with Net Debt/EBITDA at 2.3x. The transaction is expected to close in early 2027.
AbbVie acquiring Apogee Therapeutics – June 2026
AbbVie agreed to acquire Apogee Therapeutics for approximately $10.9B in equity value, with shareholders receiving $135.11 per share in cash, representing a 49% premium to the closing price on June 18, 2026. The acquisition adds Apogee’s lead Phase II asset zumilokibart, a half-life-extended monoclonal antibody targeting IL-13 for atopic dermatitis, to AbbVie’s immunology pipeline. The asset is expected to enter Phase III in 2H 2026 and is also being evaluated in asthma and eosinophilic esophagitis. Apogee’s broader pipeline includes additional immune and respiratory programs targeting dermatitis, asthma, and COPD. The transaction strengthens AbbVie’s immunology and respiratory medicine portfolio, with both companies’ boards unanimously approving the deal. The transaction is expected to close in Q3 2026.
GSK acquiring Nuvalent – June 2026
GSK agreed to acquire Nuvalent for approximately $10.6B in equity value, with shareholders receiving $124 per share in cash, representing a 40% premium to the one-day prior closing price and a 26% premium to the 30-day volume-weighted average price (VWAP). The acquisition was completed on July 15, 2026. The transaction strengthens GSK’s oncology portfolio with two registration-stage targeted therapies: Zidesamtinib (NVL-520), a ROS1 inhibitor, and Neladalkib (NVL-655), an ALK inhibitor for ALK-positive non-small cell lung cancer (NSCLC). The deal expands GSK’s precision oncology pipeline, supports growth in lung cancer, and provides potential near-term launch opportunities, with revenue contributions expected from 2027.
Lilly acquiring Kelonia – April 2026
Eli Lilly agreed to acquire Kelonia Therapeutics for $3.3B upfront, with shareholders eligible for up to $3.8B in clinical, regulatory, and commercial milestones. The transaction is expected to close in H2 2026. The acquisition adds Kelonia’s in vivo CAR-T platform, including Phase I KLN-1010, a lentiviral gene therapy targeting BCMA for multiple myeloma, and expands Lilly’s capabilities in next-generation cell and gene therapies. Kelonia’s iGPS platform enables in vivo generation of CAR-T cells by using engineered lentiviral-based particles to directly target T cells, supporting potential applications across cancer and autoimmune diseases.
Gilead acquiring Tubulis – April 2026
Gilead agreed to acquire Tubulis for $3.2B upfront, with shareholders eligible for up to $1.9B in contingent milestones. The acquisition was completed on May 21, 2026. The transaction expands Gilead’s oncology pipeline and strengthens its antibody drug conjugate (ADC) capabilities. Tubulis’ lead programs include Phase I/II TUB-040, a NaPi2b-directed topoisomerase-I inhibitor (TOPO1i) ADC for platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC), and Phase I/II TUB-030, a 5T4-targeted ADC for solid tumors. The deal also adds Tubulis’ ADC platform and additional preclinical oncology programs.
Also check out Biopharma Therapeutics and Platforms R&D Partnerships – Q2 2026 Review
